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Abstract
Background
Clinical manifestation of Systemic Lupus Erythematosus 
(SLE) may be varies in attacking various body tissue and 
organ system. Anti-dsDNA is the important antibody in 
determining diagnosis and prognosis of SLE. This study 
was conducted to explain the characteristics of anti-
dsDNA and organ system involved in SLE patients.
Method
We used quantitative descriptive analysis methods. 
Data were collected from medical records of SLE 
patients who came to Dr. Hasan Sadikin Bandung 
General Hospital Rheumatology Clinic from September to 
November 2016. Using categorical descriptive research 
equation, we found that total minimum samples were 67 
subjects. Data observed included the level of anti-dsDNA 
antibody and clinical manifestation of organ system 
involved.
Result
From 67 samples, there were 65 females which 
accounted for 97% of the research subjects. 
Distribution of organ system involved in our subjects 
was musculoskeletal (29%), mucocutaneous (27%), 
hematologic (21%), kidney (15%), neuropsychiatry (4%), 
lung involvement (4%) and cardiovascular (0%). Organ 
system involved related with strong positive anti-dsDNA 
were mucocutaneous (21,6%), hematologic (25%), 
musculoskeletal (12,5%), kidney (14,3%) and lungs 
(20%).
Conclusion
The most frequent organ system involved in SLE patients 
at our setting was musculoskeletal. The common 
organ involvement related with strong positive anti-
dsDNA were mucocutaneous, musculoskeletal, and 
hematologic.
Keywords: anti-dsDNA, involvement of organ system, 
clinical manifestation, systemic lupus erythematosus 
Introduction
Systemic Lupus Erythematosus is a chronic 
autoimmune disease marked by the production of 
autoantibody that attacks various body tissue and 
organ system (SLE).1 Prevalence of lupus disease is 
estimated around 143.7 out of 100,000 populations, 
with the largest incidence about 23.2 out of 100,000 
populations every year.2 The prevalence of SLE in 
24 countries in Asia ranges between 30-50 out of 
100,000 populations, with Shanghai ranks first for 
the highest number of prevalences.3 In the newer 
survey, Taiwan reported the prevalence, incidence, 
and mortality of lupus diseases in this country about 
97.5, 4.97, and 1.2 out of 100,000 populations, 
respectively.4 
Clinical manifestastion of SLE may vary on each 
patients, from slight discomfort to life threatening. 
It is included dysfunction on skin and mucous; 
muscoloskeletal system; kidney system;  nervous 
system; immune system;  and blood system.5clinical 
and laboratory manifestations, therapy and 
outcome were assessed. RESULTS: A cohort of 56 
patients with a mean age at disease onset of 12.6 
+/- 4.04 years (mean +/- 1SD Based on the criteria 
of revised American College of Rheumatology 
(ACR) 1997, the diagnosis of lupus disease may 
be enforced if it meets 4 of 11 criteria which are 
malar rash, discoid rash, photosensitivity, mouth 
ulcer, arthritis, serositis, renal failure, neurological 
failure, hematologic failure, immunologic failure, 
and positive antinuclear antibody (ANA).6 
The autoantibody holds essential role in 
SLE pathogenesis. It was reported by a research 
conducted in North Sweden that the autoantibody 
that damages the nucleus antigen was detected 5.6 
± 4.7 years before the diagnosis on 63% individuals 
who were later inflicted by SLE.7suggesting 
a gradual development of these diseases. 
Therefore, we sought to identify autoantibodies 
in a northern European population predating the 
onset of symptoms of SLE and their relationship 
to presenting symptoms.\\n\\nMETHODS: The 
register of patients fulfilling the American College 
of Rheumatology criteria for SLE and with a given 
date of the onset of symptoms was coanalysed with 
the register of the Medical Biobank, Ume\u00e5, 
Sweden. Thirty-eight patients were identified as 
having donated blood samples prior to symptom 
onset. A nested case-control study (1:4 The anti-
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dsDNA Antibody is an antibody that is highly related with 
SLE manifestation, especially lupus nephritis.8
In Indonesia, particularly at the Rheumatology Department 
in Hasan Sadikin General Hospital, there were no data about 
the characteristics of anti-dsDNA antibody and organ system 
involvement of Systemic Lupus Erythematosus patients. 
Knowledgement of the characteristics of anti-dsDNA antibody 
along with organ system involvement in SLE patients is 
hoped giving a better understanding of Systemic Lupus 
Erythematosus prognosis on each patients.
Method
Sampling method
We used quantitative descriptive with consecutive sampling 
methods. The minimum amount samples required in this 
research was 67 samples obtained from using the categorical 
descriptive research equation. Samples were collected from 
patients who came to Rheumatology Clinic of Hasan Sadikin 
Bandung General Hospital from September to November 
2016. Inclusion criteria for this study were: age ≥17 years 
old and diagnosed as SLE patient according to medical 
record. Samples were excluded if no data about organ system 
involvement and no data about the level of anti-dsDNA.
Data collection
Data about organ involvement were collected from patients’ 
medical records. 
Anti-dsDNA data that we analyzed were taken on the day of 
the patient came to clinics. Anti-dsDNA test were done using 
QUANTA Lite dsDNA ELISA with interpretation: negative 
(<200 IU/ml); equivocal (201-300 IU/ml); moderate positive 
(301-800 IU/ml); and strong positive(>800 IU/ml)9
Statistical analysis
The analysis was conducted descriptively by counting the 
number, percentage, and cross tabulation. The variables in 
this research were the patients’ characteristics (age, gender, 
occupation, educational attaintment), the anti-dsDNA antibody 
characteristics (negative, equivocal, moderate positive, and 
strong positive), and the patients’ clinical manifestation based 
on the involvement of organs which includes mucocutaneous, 
musculoskeletal, hematology, renal, cardiovascular, lungs and 
neuropsychiatry. The patients data were then analyzed by data 
processing application in the computer and presented in the 
form of tables.
Ethic
This study has been approved by Health Research Ethics 
Committee of Faculty of Medicine Universitas Padjadjaran 
with letter No. 922/UN6.C1.3.3/KEPK/PN/2016.
Results
Table 1. Subjects’ Demography
Characteristic
(N=67) Frequency      N(%)
Gender
Female 
Male
65 (97%)
2 (3%)
Age
    17-26 18 (27%)
    27-36 18 (27%)
    37-46 17 (25%)
    47-56 9 (13%)
    ≥57 5 (8%)
Occupation
    Indoor 61 (91%)
    Outdoor 6 (9%)
Educational Attainment
    No Education 0 (0%)
    Elementary School 10 (15%)
    Junior High School 11 (16%)
    Senior High School 34 (51%)
    University 12 (18%)
Sixty-seven subjects who meet the study criteria were 
included. We found 65 female patients (97%) of the subjects. 
The subjects’ aged were ranged between 20-60 years old. 
Most of the subjects were comprised of females of productive 
age, whose age 17-46 accounted for 79% of all subjects. Most 
research subjects were engaged in indoor activities, reaching 
up to 61 people (91%) with their occupation as housewives. 
Most achieved educational attainment was at the level of 
senior high school, reaching up to 34 people (51%), followed 
by 12 people at college level (18%).
Figure 1. Organ System Involvement
From figure 1 we can see that the most common organ 
system involvement is musculoskeletal, reaching up to 40 
cases (59.7 %), followed by mucocutaneous at 37 cases (55.2 
%), hematology at 28 cases (41.8 %), kidney at 21 cases (31.3 
%), neuropsychiatry at 5 cases (7.5 %) and lungs at 5 cases 
(7.5 %). There was no case of the cardiovascular involvement 
reported. 
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Table 2. Characteristic of Anti-dsDNA 
Anti-dsDNA 
(N=67)
            N(%)
Negative 41 (61%)
Equivocal 2 (3%)
Moderate Positive 14 (21%)
Strong Positive 10 (15%)
We found that majorly subjects has negative anti-dsDNA 
which amount for 41 subjects (61%). Only 10 subjects (15%) 
show strong-positive anti-dsDNA level. 
Figure 2. The Characteristic of Anti-dsDNA and Organ System 
Involvement
MS: musculosceletal; MC: mucocutaneous; CV:cardiovascular; 
NP: neuropsychiatry
The research data showed us that patients with negative 
anti-dsDNA had frequent clinical manifestation on 
musculoskeletal system (60.9%), mucocutaneous (56.1%), 
and hematology (31.7%). Meanwhile, patients with strong 
positive anti-dsDNA had more common clinical manifestation 
in mucocutaneous (80%), hematology (70%), musculoskeletal 
system (50 %). All neuropsychiatry involvement had negative 
anti ds-DNA. 
Discussion
We found female SLE patients were 32 folds more frequent to 
male SLE patients. This matched the previous studies, such as 
research conducted by Candace, et al which stated that female 
SLE patients were 6 times more common than male patients;2 
and research conducted by Somers, et al which stated female 
patients were 10 times more common in comparison to male 
patients10  The age of the patients ranged between 20-60 years 
old, with the highest span between 17-36 years old. It is 
consistent with the study conducted by Yazdany, et al which 
mentioned the age span of SLE patients in San Fransisco 
ranged between 24 and 60 years old. 11 However, some 
literatures mentioned that SLE patients were commonly met 
at age ranged between 15-18 years old.12  
Subjects whose have indoor occupation were up to 91%, as 
the sun light exposure may induces SLE flares. They confessed 
working as housewives with most activities were conducted 
indoor. However , it’s not impossible for these housewives to 
get sun light exposure from their activities.13n = 263 The study 
also reported that the majorly subjects had attained at least 
senior high school level education (69%). 
The most common clinical manifestation was the 
involvement of musculoskeletal (59.7%), followed by 
mucocutaneous (55.2 %) and hematology (41.8 %). It is 
consistent with the study conducted by Cabral, et al that the most 
common manifestation is the involvement of musculoskeletal 
(87.5%), followed by mucocutaneous (80.3%) and hematology 
(75%).5clinical and laboratory manifestations, therapy and 
outcome were assessed. RESULTS: A cohort of 56 patients 
with a mean age at disease onset of 12.6 +/- 4.04 years (mean 
+/- 1SD And also matched the research conducted by Jallouli, 
et al in Tunisia which states that musculoskeletal (84.2 %) 
and mucocutaneous (75.3 %) are the two most common 
manifestations.14
We found that most subjects had negative anti-dsDNA 
(61%), while moderate positive (21%) and strong positive anti-
dsDNA (15%). This could be happened due to the anti-dsDNA 
test used in this study, QUANTA Lite dsDNA ELISA, which 
has high specificity (91.0%) but low sensitivity (54.1%). Thus 
causing patients with negative anti-dsDNA not cleared from 
their SLE ailment status.15
For negative, equivocal and moderate positive anti-dsDNA, 
the most common organ involvement was musculoskeletal, 
while for strong positive anti-dsDNA, the most common organ 
involvement was the mucocutaneous. Previous researches 
stated that persistent positive anti-dsDNA tend to show the 
involvement of kidney (30.2%) while persistent negative 
anti-dsDNA tend to show more serositis (82.3%).16 However 
in our settings, kidney involvement happened in 31.3% of all 
subjects and dominated by the negative anti-dsDNA patients 
which accounted for 57.1% of all kidney involvement subjects. 
The difference might be occured due to the low sensitivity 
of our test in detecting anti-dsDNA. Study using anti-dsDNA 
test from CLIFT showed a correlation between positive anti-
dsDNA with spesific manifestations, such as proteinuria, 
haematuria, pleuritis and leukopenia. When antibodies were 
confirmed by any immunoassay, the prevalence of malar 
rash, cutaneous vasculitis, alopecia,lymphopenia and non-
haemolytic anaemia would be increased.17 Anti-dsDNA is 
also play important role in developing lupus nephritis by the 
arrangement of immune complex between anti-dsDNA with 
autoantigen located at kidneys. However, research conducted 
by Atta, et al stated that the level of anti-dsDNA is not 
always related with kidney involvement. It explained that the 
synthesis of dsDNA antibodies depends on innate and acquired 
immunity, which is induced by bacterial DNA. 18 In addition, 
Yung and Chan also stated that organ involvement not only 
depends on the existence of anti-dsDNA. Other factors, such 
as cytokine, chemokine, proteolytic enzymes and oxidation 
process play roles in developing inflammation process which 
is responsibled in damaging organs.19 
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We realized some limitation of our study. Firstly, this 
research only used secondary data from medical record and 
had relatively short data collection period, between September 
to November 2016. Furthermore, we do not analyze any other 
factors that might affects spesific organ involvement, such as 
duration of disease, medication received, amount of sun light 
exposure, etc.
 
Summary
In concluison, the most frequent organ involved in SLE 
patients at Dr. Hasan Sadikin Bandung General Hospital 
Rheumatology Clinic is musculoskeletal. Most patients showed 
negative anti-dsDNA. The most common manifestation of 
positive anti-dsDNA is the involvement of mucocutaneous, 
musculosceletal and hematologic. 
We strongly suggest for conducting more comprehensive 
study on a larger scale to provide more accurate results. 
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